CRDL

Cardiol TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.75

+139.1% vs current

Most likely

Base case

50%

Probability

Target price

$1.05

-8.7% vs current

B-

Bear case

30%

Probability

Target price

$0.48

-58.3% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Recent company news is mildly constructive because Cardiol's own May 7 release emphasizes accepted Phase II publication validation and continued MAVERIC enrollment progress [#IR-2026-05-07] [#PR-EARNINGS-2026-05-07], but the setup is still low-coverage and event-driven. There is no fresh analyst revision cluster, no SEC/insider confirmation in the packet, and no reliable post-news market-reaction data, so conviction should stay cautious rather than bullish.

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventMAVERIC enrollment keeps de-risking the lead programHigh impact

Cardiol's May 7 company release said its Phase II MAvERIC results were accepted for publication in the Journal of the American Heart Association and that the ongoing pivotal MAVERIC trial had recently surpassed 75% enrollment, which supports the clinical narrative but still leaves the eventual top-line readout as the key binary event [#IR-2026-05-07] [#PR-EARNINGS-2026-05-07].

2026-09-30catalystJAHA publication of Phase II MAvERIC data supports CardiolRx validationHigh impact

The company described the accepted Phase II MAvERIC publication as independent validation of clinical findings for CardiolRx in recurrent pericarditis, but this remains supportive evidence rather than a substitute for Phase III proof [#IR-2026-05-07] [#PR-EARNINGS-2026-05-07].

2026-12-31catalystCRD-38 remains a secondary pipeline option if development advances on scheduleHigh impact

Cardiol's prior company update said CRD-38 was being advanced toward an IND and Phase I development, which gives the stock a second long-dated pipeline catalyst if the program continues to progress [#PR-2026-04-01].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology